Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07828197). This is a study registration, not published results. Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 135 participants (ESTIMATED). Conditions: Overweight and/or Obesity, Healthy Participants. Interventions: DRUG: HDM1005. Primary outcome measures: Cmax , Up to Day 29; AUC(0-t) , Up to Day 29; AUC(0-∞) , Up to Day 29. Brief summary: The purpose of this study is to evaluate the relative bioavailability of a single subcutaneous injection of HDM1005 solution at different injection sites (upper arm and thigh)by using the abdomen subcutaneous injection as a control.